Global Nanomaterial-Based Adjuvants Vaccine Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Nanomaterial-Based Adjuvants Vaccine market size was valued at US$ 311590 million in 2024 and is forecast to a readjusted size of USD 576890 million by 2031 with a CAGR of 9.4% during review period.

Nanoparticles (NPs) can act as adjuvants for vaccines, hence they are referred to as a nano-adjuvant (NA). NPs can either encapsulate or adsorb the vaccine antigen or DNA in an appropriate formulation, thus increasing stability, cellular uptake, and immunogenicity.

Global key players of Nanomaterial-Based Adjuvants Vaccine include Emergent BioSolutions, Sanofi, etc. Global top 3 companies hold a share over 80%. North America is the largest market, with a share about 60%, followed by Europe and Japan with the share about 20% and 5%. In terms of product, Lipidosome is the largest segment, with a share about 80%. And in terms of application, the largest application is SARS-CoV-2, with a share about 75%.

Technological advancements in nanomaterial-based adjuvants vaccines are an important factor driving market development. Nano-adjuvants have the advantages of good biocompatibility, biological targeting, sustained release, safety and high efficiency, and can significantly improve the immunogenicity and protective effect of vaccines. With the continuous development and application of nanotechnology, the types and performance of nanomaterial-based adjuvants vaccines will be further improved to meet the needs of more disease prevention. As the market continues to expand and potential competitors join, competition in the nanomaterial-based adjuvants vaccines market will become more intense. Overall, the nanomaterial-based adjuvants vaccines market has broad prospects. With the advancement of technology and the increase in market demand, the market size is expected to continue to grow in the next few years.

This report is a detailed and comprehensive analysis for global Nanomaterial-Based Adjuvants Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Nanomaterial-Based Adjuvants Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (M Doses), and average selling prices (US$/Dose), 2020-2031

Global Nanomaterial-Based Adjuvants Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (M Doses), and average selling prices (US$/Dose), 2020-2031

Global Nanomaterial-Based Adjuvants Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (M Doses), and average selling prices (US$/Dose), 2020-2031

Global Nanomaterial-Based Adjuvants Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (M Doses), and ASP (US$/Dose), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Nanomaterial-Based Adjuvants Vaccine

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Nanomaterial-Based Adjuvants Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Emergent BioSolutions, Sanofi, GlaxoSmithKline Biologicals, Merck, Pfizer, Novartis, Moderna, Jiangsu Recbio Technology, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Nanomaterial-Based Adjuvants Vaccine market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Aluminium Hydroxides
Aluminium Phosphate
Lipidosome
Others

Market segment by Application
Pneumococcus
Human Papilloma Virus
DTaP
Viral Hepatitis TypeA
Viral Hepatitis TypeB
SARS-CoV-2
Others

Major players covered
Emergent BioSolutions
Sanofi
GlaxoSmithKline Biologicals
Merck
Pfizer
Novartis
Moderna
Jiangsu Recbio Technology

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Nanomaterial-Based Adjuvants Vaccine product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Nanomaterial-Based Adjuvants Vaccine, with price, sales quantity, revenue, and global market share of Nanomaterial-Based Adjuvants Vaccine from 2020 to 2025.

Chapter 3, the Nanomaterial-Based Adjuvants Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Nanomaterial-Based Adjuvants Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Nanomaterial-Based Adjuvants Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Nanomaterial-Based Adjuvants Vaccine.

Chapter 14 and 15, to describe Nanomaterial-Based Adjuvants Vaccine sales channel, distributors, customers, research findings and conclusion.